Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Will Slew of Patent Bills Lower Drug Prices?

Executive Summary

Legislation is targeting a wide range of patent practices, from product hopping to patent infringement settlements and inter partes review.

You may also be interested in...



US Patent Reform Legislation Threatened By Biden Support For Vaccine IP Waiver, Republicans Say

At hearing on Humira patent thicket, House Republicans express concern that Democrats’ support for transferring US intellectual property rights for COVID-19 vaccines to other countries is a bad sign for collaboration on legislation to reform patent abuses.

FTC's First Product Hopping Complaint Targets Safety Claims For Suboxone Film Formulation

Commission files complaint as it reaches $50m settlement with Reckitt Benckiser.

Patent Thicketing Provision Cut From Bill Passed By US Senate Judiciary Committee

Legislation was also revised to enable manufacturers to justify withdrawing, discontinuing or switching product for follow-on; bills restricting citizen petitions, tribal sovereign immunity also clear committee.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS125575

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel